Stockwinners Market Radar for June 10, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Kiora Pharmaceuticals Inc trading halted, news pending

19:21 EDT CoreCivic discloses termination notice of ICE contract, sees 38c-41c EPS impact - The company states: "CoreCivic received notification today from U.S. Immigration and Customs Enforcement, or ICE, that the agency intends to terminate an inter-governmental service agreement between CoreCivic and ICE for services at the South Texas Family Residential Center in Dilley, TX effective in 60 days, or on or about August 9, 2024. For the year ended December 31, 2023, and for the quarter ended March 31, 2024, total revenues at the Facility were $156.6 million and $39.3 million, respectively. Given that the notice of termination was received today and based on cost uncertainties associated with the closure, CoreCivic is suspending its financial guidance for 2024. However, we estimate the annualized financial impact to be a reduction to earnings per share of approximately 38c-41c."

18:44 EDT HP Inc. CEO: Starting to see growth of PCs again - In an interview on CNBC's Mad Money, Enrique Lores said HP Inc. has very good momentum heading into the second half of the year. It is building models into PCs that will learn how the user works and adapt to that, he noted.

18:07 EDT SAIC CFO buys $229.7K in common stock - In a regulatory filing, SAIC disclosed that its CFO Prabu Natarajan bought 2K shares of common stock on June 10th in a total transaction size of $229.7K.

17:51 EDT CACI awarded $450M Air Force contract - CACI was awarded a maximum $450M firm-fixed-price, firm-fixed-price-level-of-effort, fixed-price-incentive-fee, cost, indefinite-delivery/indefinite-quantity contract for Joint Navigation Warfare Center IV. This contract provides research and development support services for the Joint Navigation Warfare Center. Work will be performed in Albuquerque, New Mexico, and is expected to be completed by February 15, 2034. This contract was a competitive acquisition, and five offers were received. Fiscal 2024 operation and maintenance funds in the amount of $14.26M are being obligated at time of award. The Space Acquisition Integration Office is the contracting activity.

17:30 EDT e.l.f. Beauty director sells $2.0M in common stock - In a regulatory filing, e.l.f. Beauty discosed that its director Richard Wolford sold 11.1K shares of common stock on June 7th in a total transaction size of $2.0M.

17:19 EDT Noodles & Co. names Britain Peakes to board as part of pact with Hoak & Co. - Noodles & Company has appointed Britain Peakes as a director on its Board of Directors, effective June 10, 2024. Ms. Peakes is a seasoned finance and investment professional with experience in both private and public markets. As a principal investor at Hoak & Co., she oversees a comprehensive range of responsibilities, including sourcing, due diligence, transaction negotiation and execution, portfolio management, and financial analysis across real estate, private equity, and public equity sectors. Before her tenure at Hoak & Co., Ms. Peakes held various roles at HBC Investments, Blackhill Partners, ACS, RM Crowe, and Ernst & Young. Ms. Peakes joins the Board as part of a Support Agreement entered into between Noodles & Company and Hoak Public Equities, L.P., which owns approximately 9.48% of the Company's outstanding shares.

17:01 EDT VS Media announces 1-for-7 share combination - VS Media Holdings Limited announced that it plans to implement a 1-for-7 share combination of its Class A ordinary shares and Class B ordinary shares effective on June 17, 2024. Beginning with the opening of trading on June 17, 2024, the company's Class A Ordinary Shares will begin trading on a post-Share Combination basis on the Nasdaq Capital Market under the same symbol "VSME", but under a new CUSIP number of G9517U202. The objective of the Share Combination is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market. Upon the effectiveness of the Share Combination, every seven issued and outstanding Class A Ordinary Shares of no par value each and Class B Ordinary Shares, no par value per share will automatically be converted into one issued and outstanding Class A Ordinary Share of no par value each and Class B Ordinary Shares, no par value per share, respectively. No fractional shares will be issued as a result of the Share Combination. Instead, any fractional shares that would have resulted from Share Combination will be rounded up to the next whole number. The Share Combination affects all shareholders uniformly and will not alter any shareholder's percentage interest in the company's outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares. The Share Combination was approved by the company's board of directors on June 5, 2024, and its shareholders on June 10, 2024.

16:49 EDT Autodesk says provided SEC with documents related to internal investigation - In a regulatory 10-Q filing, the company states: "In early March 2024, the Audit Committee of Autodesk's Board of Directors commenced an internal investigation with the assistance of outside counsel and advisors regarding the Company's free cash flow and non-GAAP operating margin practices. On March 8, 2024, the Company voluntarily contacted the U.S. Securities and Exchange Commission to inform it of the Internal Investigation. On April 3, 2024, the United States Attorney's Office for the Northern District of California contacted the Company regarding the Internal Investigation. The Company voluntarily provided the SEC and USAO with certain documents relating to the Internal Investigation and will continue to cooperate with the SEC and USAO. At this stage, the Company cannot reasonably estimate the amount of any possible financial loss that could result from this matter."

16:42 EDT Genfit SA (ADR) trading halted, news pending

16:39 EDT Musk to ban Apple devices at his companies if they integrate OpenAI at OS level - Tesla (TSLA) CEO Elon Musk said in a post on X, formerly Twitter, that if Apple (AAPL) integrates Microsoft-backed (MSFT) OpenAI at the OS level, then Apple devices will be "banned" at his companies. "That is an unacceptable security violation," Musk said. "And visitors will have to check their Apple devices at the door, where they will be stored in a Faraday cage." Reference Link

16:34 EDT AT&T backs FY24 CapEx view $21B-$22B, on track to achieve financial guidance - Pascal Desroches, CFO, AT&T, will speak tomorrow at the Bank of America C-Suite TMT Conference where he will provide an update to shareholders. AT&T remains on track to achieve its financial guidance. The company remains confident in its ability to deliver on all of the financial guidance shared during its earnings report in April 2024. AT&T also remains focused on driving incremental efficiencies through its goal of $2B+ in run-rate cost savings by mid-2026. The company is on track to achieve net-debt to adjusted EBITDA in the 2.5x range in the first half of 2025. It also plans to continue addressing short-term financing obligations as it shapes an even more sustainable and ratable free cash flow cadence. AT&T continues to make critical investments in its wireless and fiber future. Over the past five years, from 2019 to 2023, AT&T invested $145B+ primarily in its wireless and wireline networks, including capital investments and acquisitions of wireless spectrum3. To support its ongoing investment in 5G and fiber, the company continues to expect 2024 capital investment in the $21B-22B range.

16:31 EDT Real Brokerage is set to join the Russell 3000 Index - The Real Brokerage is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. "We're honored to be joining the Russell 3000(R) Index, a milestone that reflects a decade of hard work and dedication building Real into the real estate technology leader it is today," said Tamir Poleg, Real's Chief Executive Officer. "Our success wouldn't be possible without the unwavering commitment of our agents and employees. Joining this prestigious index will amplify Real's visibility within the investment community, enabling us to share our story and unique agent value proposition with a broader audience."

16:23 EDT Domo partners with phData to simplify data management - The company states: "Domo announced that phData, a full-service AI and data analytics consulting company, has partnered with Domo to help its users simplify data management and get actionable intelligence faster with the Snowflake AI Data Cloud and Domo. With more than 600 employees, phData is bringing together its analytics consulting projects for customers to utilize Snowflake's AI Data Cloud and the power of Domo's platform. phData relies on Domo's platform to provide real-time data to all employees, which empowers informed decision-making and drives business impact. Supported by a range of flexible AI services, Domo enables companies to utilize, expand, act on and automate actions based on corporate data, all while ensuring secure, transparent and permission-based AI implementation."

16:21 EDT Middlesex Water names Mohammed Zerhouni as CFO - Middlesex Water has named Mohammed Zerhouni as its new senior VP, CFO and treasurer effective June 24, as part of its ongoing strategic succession planning efforts. Zerhouni joins Middlesex following a search for a successor to senior VP, treasurer and CFO, A. Bruce O'Connor, who will retire from the company effective June 21 after 34 years of service.

16:18 EDT Brookdale Senior Living reports May occupancy - May 2024 Observations: Sequentially, May weighted average occupancy increased 20 basis points while month end occupancy increased 30 basis points, supported by ongoing improvement in resident retention. May weighted average occupancy reflected a continued outperformance versus pre-pandemic normal seasonality and represented the company's thirty-first consecutive month of year-over-year weighted average occupancy growth. Second quarter-to-date weighted average occupancy increased 160 basis points to 78.0% compared to 76.4% for the comparable period of 2023.

16:16 EDT First Trust Equity Income raises quarterly dividend to 35c per share from 31.5c - The distribution will be payable on June 28, 2024, to shareholders of record as of June 21, 2024. The ex-dividend date is expected to be June 21, 2024.

16:10 EDT Syntec Optics CFO Robert Nelson departs, Dean Rudy succeeds - Syntec Optics named Dean Rudy CFO, effective June 10. Rudy succeeds Robert Nelson. Rudy brings over 30 years of experience. His last assignment was CFO for Auction Direct USA, a multi-state used car superstore company.

16:08 EDT GE HealthCare says IGT to be combined with Ultrasound segment in 3Q24 - GE HealthCare announced that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale. This also highlights the depth of internal talent that GE HealthCare is building to strengthen focus on delivering for patients and customers. These changes will be effective July 1, 2024. IGT, a $1.6B subsegment of Imaging, will be combined with the Ultrasound segment in the third quarter of 2024, to form a global business with more than $5B in annual revenue. GE HealthCare is aligning IGT with Ultrasound to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. Aligning IGT and Ultrasound positions GE HealthCare to be more agile and address future imaging needs using these real-time modalities in both inpatient and outpatient settings. Without IGT, Imaging will remain GE HealthCare's largest segment with more than $8.9B in annual revenue. This segment will enhance focus on solutions centered on surgical and interventional procedures, particularly interventional cardiology and structural heart, while continuing Ultrasound's diagnostic leadership. Peter Arduini, chief executive officer of GE HealthCare, said, "Roland and Phil will bring fresh viewpoints, global perspective, and deep industry expertise to our Imaging segment and new Ultrasound and IGT segment. Elevating leaders who have a deep understanding of our customers' needs, market trends, and our strategic focus will help enable us to accelerate innovation and growth. Roland and Phil are proven leaders who are well positioned to take on these new opportunities, drive our precision care strategy, and deliver for patients and customers." GE HealthCare expects to provide recast financial results to reflect the movement of IGT from Imaging to the new Ultrasound and IGT segment in its filings with the U.S. Securities and Exchange Commission for third quarter 2024.

16:06 EDT 2U announces 1-for-30 reverse stock split - 2U announced that it will proceed with a 1-for-30 reverse stock split of its outstanding shares of common stock following approval by its Board of Directors. This ratio is within the range approved by stockholders at the annual meeting of 2U shareholders held on May 20, 2024. The Reverse Stock Split is expected to become effective at 5 p.m., Eastern Time, on June 13, 2024. 2U expects the Common Stock will begin trading on a post-split basis at the market open on June 14, 2024 under the symbol "TWOU" with the new CUSIP number 90214J 200. The primary goal of the Reverse Stock Split is to increase the per share market price of the Common Stock to regain compliance with Nasdaq's minimum bid price requirement for continued listing on The Nasdaq Global Select Market

16:02 EDT Ubisoft highlights 'Star Wars,' 'Assassin's Creed' at Forward event - At its Ubisoft Forward event, Ubisoft made a number of announcements pertaining to its upcoming video game slate. Highlights from the event include: a new story and gameplay trailer for "Star Wars: Outlaws," out August 30, 2024; an update for its new free-to-play shooter "XDefiant"; the announcement a free new content update for "Prince of Persia: The Lost Crown" that has a boss rush mode and additional puzzle and platform challenges, available today; the announcement of new story downloadable content for "The Lost Crown," out September 2024; a new trailer for "The Rogue Prince of Persia" and its upcoming new content update; a teaser for the upcoming remake of "Prince of Persia: The Sands of Time," out in 2026; the reveal of new strategy game "Anno 117 Pax Romana," out in 2025 on PC and consoles; and a deeper look at "Assassin's Creed Shadows," out November 15, 2024.

14:49 EDT Apple previews iOS 18 with 'biggest-ever redesign of Photos' - Apple previewed iOS 18, which it calls "a major release that features more customization options, the biggest redesign ever of the Photos app, new ways for users to manage their inbox in Mail, Messages over satellite, and so much more." Apple said: "Users will be able to arrange apps and widgets in any open space on the Home Screen, customize the buttons at the bottom of the Lock Screen, and quickly access more controls in Control Center. Photo libraries are automatically organized in a new single view in Photos, and helpful new collections keep favorites easily accessible. Mail simplifies the inbox by sorting email into categories using on-device intelligence, and all-new text effects come to iMessage. Powered by the same groundbreaking technology as existing iPhone satellite capabilities, users can now communicate over satellite in the Messages app when a cellular or Wi-Fi connection isn't available." Craig Federighi, Apple's senior vice president of Software Engineering, said: "We are thrilled to introduce iOS 18. It is a huge release with incredible features, including new levels of customization and capability, a redesigned Photos app, and powerful ways to stay connected with Messages. There are so many benefits for everyone. This release also marks the beginning of a tremendously exciting new era of personal intelligence with Apple Intelligence delivering intuitive, powerful, and instantly useful experiences that will transform the iPhone experience, all with privacy at the core. We can't wait for users to experience it." The developer beta of iOS 18 is available through the Apple Developer Program starting today, and a public beta will be available through the Apple Beta Software Program next month at beta.apple.com. iOS 18 will be available this fall as a free software update for iPhone Xs and later. Apple Intelligence will be available in beta on iPhone 15 Pro, iPhone 15 Pro Max, and iPad and Mac with M1 and later, with Siri and device language set to U.S. English, as part of iOS 18, iPadOS 18, and macOS Sequoia this fall.

14:47 EDT Apple previews watchOS 11 for Apple Watch - Apple previewed watchOS 11, with features for Apple Watch that "build on its leading sensor technology, advanced algorithms, and science-based approach to offer breakthrough insights into users' health and fitness, and more personalization than ever." The new Vitals app surfaces key health metrics and context to help users make more informed day-to-day decisions, and the ability to measure training load offers a game-changing new experience when working out for improved fitness and performance. Activity rings are even more customizable, the Smart Stack and Photos face use intelligence to feature more individualization, and Apple Watch and the Health app on iPhone and iPad offer additional support for users who are pregnant. Check In, the Translate app, and new capabilities for the double tap gesture come to Apple Watch for added connectivity and convenience. A public beta will be available to watchOS users next month. watchOS 11 will be available this fall as a free software update for Apple Watch Series 6 or later paired with iPhone Xs or later, running iOS 18. Some features may not be available in all regions or all languages, or on all devices.

14:46 EDT Apple introduces 'Apple Intelligence' personal intelligence system - Apple introduced "Apple Intelligence," which it calls "the personal intelligence system for iPhone, iPad, and Mac that combines the power of generative models with personal context to deliver intelligence that's incredibly useful and relevant." Apple said: "Apple Intelligence is deeply integrated into iOS 18, iPadOS 18, and macOS Sequoia. It harnesses the power of Apple silicon to understand and create language and images, take action across apps, and draw from personal context to simplify and accelerate everyday tasks. With Private Cloud Compute, Apple sets a new standard for privacy in AI, with the ability to flex and scale computational capacity between on-device processing and larger, server-based models that run on dedicated Apple silicon servers." Tim Cook, Apple's CEO, added: "We're thrilled to introduce a new chapter in Apple innovation. Apple Intelligence will transform what users can do with our products - and what our products can do for our users. Our unique approach combines generative AI with a user's personal context to deliver truly helpful intelligence. And it can access that information in a completely private and secure way to help users do the things that matter most to them. This is AI as only Apple can deliver it, and we can't wait for users to experience what it can do." Powered by Apple Intelligence, Siri "becomes more deeply integrated into the system experience," Apple said. Apple stated: "With richer language-understanding capabilities, Siri is more natural, more contextually relevant, and more personal, with the ability to simplify and accelerate everyday tasks. It can follow along if users stumble over words and maintain context from one request to the next. Additionally, users can type to Siri, and switch between text and voice to communicate with Siri in whatever way feels right for the moment. Siri also has a brand-new design with an elegant glowing light that wraps around the edge of the screen when Siri is active."

14:41 EDT Apple says Apple Intelligence to be available in English this summer

14:37 EDT Apple says ChatGPT coming to Siri - Apple (AAPL) said that ChatGPT, made by Microsoft-backed (MSFT) OpenAI, is coming to Siri.

14:32 EDT Arcutis announces new long-term data from study of roflumilast in AD - Arcutis Biotherapeutics announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15% in adults and children ages 6 years and older with Atopic Dermatitis, or AD, presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference. In the study, roflumilast cream was well-tolerated, with no new safety signals observed over 56 weeks of treatment. Efficacy was not only maintained but improved over time, with 56.6% of participants who continued use of roflumilast cream from the initial trial and 53.8% of participants who switched to roflumilast cream 0.15% from vehicle after the initial trial achieving validated Investigator Global Assessment-Atopic Dermatitis success, defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline, at Week 56, the company announced.

14:25 EDT Correction: FedEx board increases quarterly dividend 10%

14:17 EDT FedEx board increases quarterly dividend 10% to 48c per share - The board of directors of FedEx approved an increase in the annual dividend rate on FedEx Corp. common stock of 10%, or 48c per share, to $5.52 per share for fiscal 2025 "in line with the company's continued focus on delivering stockholder value. The board also declared a quarterly cash dividend of $1.38 per share on FedEx Corp. common stock. The dividend is payable July 9 to stockholders of record at the close of business on June 24. "We remain committed to creating value for our stockholders. This dividend increase is an important component of our disciplined approach to capital allocation, which also includes share repurchases and prudently investing in our business," said John Dietrich, executive vice president and chief financial officer of FedEx Corp.

14:12 EDT Apple says Apple Intelligence can carry out tasks on user's behalf - Says designing AI to help users "accomplish more while saving time." Says Apple Intelligence "grounded" in personal information and context.

14:08 EDT Apple announces Apple Intelligence suite of AI features - Says Apple Intelligence places generative models at core of iPhone, iPad, and Mac products. Says Apple Intelligence draws on personal context to help users complete tasks and protect their privacy.

14:05 EDT Apple says betas for all new OS products coming in July, full releases this Fall

14:03 EDT Apple unveils Game Porting Toolkit 2, says new 'Assassin's Creed' coming to Mac - Apple (AAPL) says Toolkit 2 makes it even easier for game developers to bring games to Mac and bring Mac games to iPad and iPhone. Says "Frostpunk 2" coming to Mac next month. Says Ubisoft's (UBSFY) "Prince of Persia: The Lost Crown" and "Assassin's Creed Shadows" coming to Mac. Says new "Assassin's Creed" launching on Mac on November 15, 2024, the same day as PC and consoles. Says "Assassin's Creed Shadows" also coming to iPad.

13:57 EDT Apple introduces Passwords app - Says Passwords app helps users access all their passwords across devices in a single place.

13:53 EDT Apple unveils macOS Sequoia - Says Sequoia comes with math notes and updated messages features. Says Sequoia introduces more new features, including Continuity, which helps users use better Apple products together.

13:50 EDT GSK 'welcomes' plaintiff's voluntary dismissal of Kasza Zantac case - GSK issued the following statement: "GSK plc welcomes the plaintiff's voluntary dismissal of the next Zantac case, or "Kasza," which was scheduled to start trial in Illinois state court on June 10, 2024. GSK did not settle Ms. Kasza's claim and has not paid anything in exchange for the voluntary dismissal. Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders."

13:40 EDT Apple says Health app on watchOS to come with better pregnancy tracking features - Says users can customize heart rate notifications.

13:38 EDT Apple announces software updates across Home products - Apple announced software updates across its Home products that it says "supercharge entertainment and deliver greater everyday convenience." Apple added: "With tvOS 18, intelligent new features like InSight - and updates to Enhance Dialogue and subtitles - level up cinematic experiences, while new Apple Fitness+, Apple Music, and FaceTime capabilities get even better on users' biggest screen. The Home app gains new features with iOS 18, like guest access and hands-free unlock with home keys, delivering effortless and secure access to the home. tvOS 18 and iOS 18 are available as developer betas today, and will be available as free software updates this fall."

13:35 EDT Apple says Enhance Dialogue coming to more living room devices - Says tvOS now supports 21:9 presentation for projectors.

13:32 EDT Apple says Voice Isolation coming to AirPods Pro - Says Voice Isolation removes background noise around users to deliver "the best call quality." Says users can nod yes or shake no to interact with Siri while using AirPods.

13:29 EDT Globalstar up 1% as Apple announces satellite texting for iMessage at event - Shares of Globalstar are up 1c, or 1%, to $1.10 in afternoon trading.

13:26 EDT Apple announces new Wallet features Tap to Cash and Pay online

13:23 EDT Apple says Apple Vision Pro coming to China, Japan, Singapore June 28 - Says visionOS 2 adding train support for travel mode on Vision Pro. Says visionOS2 makes it easier for developers to build apps for Vision Pro. Says Apple Immersive Pro getting new partners, including BlackMagic Design and Red Bull. Says Vision pro coming to Australia, Canada, France, Germany, and U.K. on July 12.

13:18 EDT Apple says iOS 18 to come with more customization features - Says iOS 18 users can organize app icons on home screen any way they like. Says updated control center allows developers to add app-specific features to control center.

13:15 EDT Apple says Apple Vision Pro cocming to China, Japan, Singapore June 28 - Says visionOS 2 adding train support for travel mode on Vision Pro. Says visionOS2 makes it easier for developers to build apps for Vision Pro. Says Apple Immersive Pro getting new partners, including BlackMagic Design and Red Bull. Says Vision pro coming to Australia, Canada, France, Germany, and U.K. on July 12.

12:05 EDT Seacor Marine rises 13.9% - Seacor Marine is up 13.9%, or $1.65 to $13.48.

12:03 EDT Texas Pacific Land rises 23.4% - Texas Pacific Land is up 23.4%, or $136.40 to $718.47.

12:02 EDT Anywhere Real Estate falls -10.6% - Anywhere Real Estate is down -10.6%, or -41c to $3.42.

12:00 EDT GameStop falls -11.8% - GameStop is down -11.8%, or -$3.33 to $24.89.

11:51 EDT Pfizer 'very confident we will make our numbers' - Pfizer previously provided FY24 adjusted EPS guidance of $2.15-$2.35 and revenue guidance of $58.5B-$61.5B. Comments taken from the Goldman Sachs Annual Global Healthcare Conference.

11:48 EDT Electra Battery Materials receives $5M from Government of Canada - Electra Battery Materials has received $5M in contribution funding from Natural Resources Canada to support the development of its proprietary battery materials recycling technology. In 2023, the Company successfully operated a battery materials recycling demonstration plant in a batch process at its refinery complex, processing more than 40 tonnes of end-of-life battery scrap, known as "black mass," and producing high-quality nickel, cobalt and lithium products. Electra is accelerating the next phase of its recycling project to demonstrate on a continuous basis that the Company's hydrometallurgical black mass process is scalable, profitable, and can be implemented at other locations. The Government of Canada, through National Resources Canada's Critical Minerals Research, Development and Demonstration program, has committed funding of $5M for this project, which will be based at the Company's fully permitted property about five hours north of Toronto, Ontario, in Temiskaming Shores. Recycling and recovery of these critical metals would reduce greenhouse gas emissions in the EV supply chain and decrease reliance on foreign countries for critical minerals.

11:12 EDT Trump Media announces filing of amended S-1 with SEC - Trump Media & Technology Group - operator of the Truth Social platform - announced it has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission to register, for resale or initial issuance, certain shares of common stock and warrants of the company following the consummation of the company's business combination with Digital World Acquisition Corp. on March 25. "The Amended Registration Statement amends the registration statement filed on April 15, 2024; the number of shares of common stock that TMTG seeks to register is unchanged. Today's filing follows and incorporates a re-audit of the Company's financial statements for the years ended December 31, 2023, and December 31, 2022, conducted by the Company's independent auditor, Semple, Marchal & Cooper LLP, or 'SMC,' in accordance with Public Company Accounting Oversight Board standards. As part of the Amended Registration Statement, all securities being registered are either held by or underlie securities held by existing security holders of TMTG. TMTG will not receive any proceeds from the sale or resale of securities by the selling security holders pursuant to this Amended Registration Statement, except in connection with any possible future exercise for cash of any outstanding warrants. The listing of an individual as a 'selling securityholder' in the Amended Registration Statement does not mean such individual or entity will sell their shares or is planning to sell their shares. Notwithstanding registration of securities on the Amended Registration Statement, TMTG's directors and officers, its affiliate President Donald J. Trump and certain other securityholders will remain subject to a lockup period or otherwise restricted from selling any shares at this time. The Amended Registration Statement relating to these securities has been filed with the SEC but has not yet been declared effective. These securities registered may not be sold nor may offers to buy be accepted until the Amended Registration Statement becomes effective. The Amended Registration Statement is subject to further amendment and completion," the company stated.

10:50 EDT Digital Health Acquisition Corp trading halted, volatility trading pause

10:31 EDT DTE to build energy storage center at site of retired Trenton Channel plant - DTE Energy will convert a portion of its retired Trenton Channel coal power plant site to house a 220-megawatt battery energy storage center. When complete in 2026, the energy storage center is expected to be the largest standalone battery energy storage project in the Great Lakes region. The center will have the capacity to store 220 megawatts of electricity, enough to power nearly 40,000 homes.

10:25 EDT Hudson Acquisition I Corp trading resumes

10:21 EDT Baijiayun Group Ltd trading halted, volatility trading pause

10:05 EDT Studio City falls -8.7% - Studio City is down -8.7%, or -66c to $6.90.

10:04 EDT Methode Electronics falls -17.8% - Methode Electronics is down -17.8%, or -$2.01 to $9.31.

10:03 EDT Rogers announces 'blockbuster' deals with NBCUniversal, Warner Bros. Discovery - Rogers Communications (RCI) announced "blockbuster" multi-year deals with Comcast's (CMCSA) NBCUniversal and Warner Bros. Discovery (WBD) to bringlifestyle and entertainment content to Canadians on their platform of choice. "Starting September 2024, the company is launching NBCUniversal's Bravo channel in Canada and will become the English-language television content rights holder in Canada, featuring the best of unscripted programming, which will include new seasons of Bravo's hit franchise series. Starting January 2025, Rogers will be the home of Warner Bros. Discovery's suite of English-language U.S. lifestyle and factual brands, including HGTV, The Food Network, and much more," the company stated.

10:01 EDT Cactus rises 13.0% - Cactus is up 13.0%, or $6.08 to $52.90.

09:54 EDT Chatham Lodging falls -8.8% - Chatham Lodging is down -8.8%, or -75c to $7.82.

09:51 EDT AerSale opens new location in Millington, Tennessee - AerSale announces the opening of its newest location in Millington, Tennessee, with its first aircraft induction. Founded in 1917 the Millington-Memphis Airport is one of the oldest airports in the United States and has a long legacy of training military aviation personnel dating back to World War I. The airport hosts one of the longest runways in Tennessee and is conveniently located near AerSale's 320,000 sq. ft. parts distribution facility in Memphis, TN. This newest location has been renovated to support AerSale's customers. The upgrades to the facility include improvements throughout the space, as well as the addition of state-of-the-art equipment, a new parts paint booth and office space. The 112,000 sq. ft. complex will cater to narrow-body maintenance, modifications, and heavy MRO activities, as well as aircraft storage and disassembly - augmenting AerSale's already robust MRO operations in both Goodyear, AZ and Roswell, NM. Furthermore, the facility will offer MRO services for structural components and other aircraft parts

09:48 EDT Diamond Offshore rises 9.4% - Diamond Offshore is up 9.4%, or $1.31 to $15.24.

09:47 EDT Cactus rises 10.3% - Cactus is up 10.3%, or $4.82 to $51.64.

09:46 EDT BioSig Technologies appoints Ferdinand Groenewald to interim CFO - BioSig Technologies announced the appointment of Mr. Ferdinand Groenewald to the position of interim CFO. He currently serves as Vice President, Finance at Alaunos Therapeutics.

09:39 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:36 EDT Knightscope awarded contract from Ivy League school - Knightscope announces a new contract from an Ivy League school for a custom K1 Blue Light Tower. This purchase is part of the university's initial evaluation that is expected to lead to a larger rollout across campus in the near future.

09:32 EDT Vuzix announces smart glasses reorders from Xander - Vuzix announced that Xander has placed multiple follow-up orders for Vuzix Shield smart glasses as it increases customer shipments of its XanderGlasses, a smart glasses solution that utilizes Xander's embedded software that displays real-time captions of in-person conversations to help people with hearing loss.

09:23 EDT IGC Pharma publishes study of CYP2C9 PK of delta 9 THC - IGC Pharm announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics or PK of delta-9-tetrahydrocannabinol THC and its active metabolite in Alzheimer's disease or AD patients. The publication is titled "A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ?-9-tetrahydrocannabinol" and is available at The article highlights the importance of understanding genetic variations in CYP2C9, an enzyme crucial for drug metabolism, and its impact on the efficacy and safety of treatments involving THC. IGC Pharma's leading drug candidate IGC-AD1 was tested in a Phase 1 multiple ascending dose trial with a Puerto Rican population. The study examined the effect of CYP2C9 polymorphisms on THC metabolism in AD patients. Key findings revealed significant variations in THC and OH-THC half-life among different CYP2C9 phenotypes, suggesting the need for personalized dosing strategies in AD patients. Ram Mukunda, CEO of IGC Pharma, commented, "We are very pleased to announce the publication in the prestigious European Society of Medicine journal. This publication is a testament to our dedication to pioneering research in Alzheimer's disease. Understanding the genetic factors influencing drug metabolism is critical for developing safe and effective treatments. We are proud to contribute to the scientific community with this important study, reinforcing our commitment to enhancing patient care and delivering shareholder value through scientific innovation."

09:10 EDT KindlyMD, Curaleaf collaborate to expand patient education on medical cannabis - KindlyMD (KDLY) announced a strategic collaboration with Curaleaf Holdings (CURLF). Under the terms of the collaboration, KindlyMD and Curaleaf will work together to provide educational resources and information with a community perspective on holistic pain management and treatment. KindlyMD providers will introduce the KindlyMD Complete Care program, which will afford patients in Utah County and its surrounding areas the option to more easily access the medical cannabis care options offered by Curaleaf pharmacists.

09:09 EDT TSA awards Accenture blanket purchase deal with $170M ceiling value - Accenture Federal Services has been awarded a Transportation Security Administration TSA Security Operations SO Flexible Agile Scalable Teams FAST Blanket Purchase Agreement with a ceiling value of $170M . TSA SO is responsible for security of the nation's transportation systems to ensure freedom of movement for people and commerce, including checkpoint and baggage screening at approximately 440 airports in the U.S. and oversight of more than 280 airports globally. TSA SO is also responsible for ensuring all modes of transportation, including freight railroad, passenger rail, mass transit, maritime, and pipelines comply with domestic and global regulatory requirements.

09:07 EDT MKS Instruments to build Super Center factory in Malaysia - MKS Instruments is set to build a Super Center factory in Penang, Malaysia to support wafer fabrication equipment production in the region and globally. The development plan is to construct the new facility in three phases, with groundbreaking expected to commence in early 2025.

09:06 EDT ResMed announces PAP therapy reduces hospitalizations by 31%, ER visits by 23% - In collaboration with leading medical researchers from around the world, ResMed presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health. "The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA," said Carlos Nunez, MD, ResMed's Chief Medical Officer. "The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining critical areas such as the effect of demographic factors like gender on sleep health. The body of knowledge we have created and are continually expanding with research partners who are highly respected in their fields helps ResMed and the medical community achieve the goal of helping people live their healthiest lives."

09:05 EDT Micron partners with Clarity Credit Union to boost access to capital - Micron Technology announced a $4M deposit with Clarity Credit Union, a certified Community Development Financial Institution, CDFI, in Idaho. With this deposit, Micron has reached its commitment established with the Economic Opportunity Coalition, EOC, to place $20M with CDFIs. Today's announced deposit will help Clarity Credit Union offer products, services and financial literacy education to members in the state's rural areas who may lack access to conventional financial services. To reach its EOC commitment, over the last year Micron deposited $10M with Carver Federal Savings Bank, $3M with Syracuse Cooperative Federal and $3M with Locus.

09:05 EDT LPL Financial: Lifetime Legacy joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor David Hilbig has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported serving approximately $275 million in advisory, brokerage and retirement plan assets and joins LPL from Corebridge Financial, formerly Valic, a subsidiary of AIG. Hilbig, who lives in The Woodlands, Texas area and maintains a registered office in Mundelein, Ill., has more than 20 years of experience crafting personalized financial strategies tailored to each client's unique needs and aspirations. He takes a holistic approach to financial planning, encompassing areas such as wealth management, retirement planning, investment advisory and risk management. By carefully assessing a client's financial situation and priorities, he strives to provide comprehensive solutions that align with their short-term objectives and long-term visions.

09:04 EDT Movano, MIT partner on MAESTRO study - In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring capabilities of Movano's Evie Ring. The MAESTRO study, a comprehensive study using the latest advancements in medical research, will recruit 300 adults aged 18-35 across four distinct cohorts: those with acute Lyme disease, chronic Lyme disease, long COVID, and a control group. With an estimated 40 million Americans grappling with the debilitating effects of long COVID, and over 600,000 new cases per year of Lyme disease, 10-15% of which will manifest as chronic Lyme, the long-term health impacts of these conditions are still shrouded in mystery. This study holds the promise of unlocking vital answers.

09:03 EDT Advantage Solutions sells Strong Analytics to OneSix, terms not disclosed - Advantage Solutions has sold Strong Analytics, a designer and developer of custom software solutions, to OneSix. Terms of the sale, which closed June 7, were not disclosed. Strong Analytics, which Advantage acquired in 2021, provides a range of data science services primarily to brands in the pharmaceutical, marketing and hospitality industries. A substantial majority of the brands Strong serves fall outside of Advantage's core retailer and consumer packaged goods clients. As part of the sale, Strong will fold into OneSix, a Chicago-based data engineering and technology company. The sale advances Advantage's broader growth acceleration plan, which includes efforts to simplify its portfolio - enabling greater focus on the company's core capabilities while creating the capacity to strengthen its balance sheet, drive productivity and fuel growth. The company intends to use the majority of proceeds from the transaction to reinvest in its business and reduce its debt as it continues to progress toward its target of achieving a net-debt-to-adjusted-EBITDA ratio of less than 3.5 times.

09:02 EDT Digital Turbine names Michael Akkerman as Chief Business Officer - Digital Turbine (APPS) is excited to announce the appointment of Michael Akkerman as the company's new Chief Business Officer. In this role, Michael will lead DT's global go-to-market efforts, including sales, partnerships, marketing, product, and business operations. Most recently, Michael served as GM, Mobility Advertising at Uber (UBER), where he led the vision and strategy for Uber's emerging advertising business across its global ride-hailing app.

09:01 EDT Stran & Company expands multiple contracts with industry-leading customers - Stran & Company announced that it has recently secured multiple expanded contracts with industry-leading, enterprise-level customers. These customers span multiple sectors and geographies, demonstrating Stran's position as a leader in the promotional products industry, as well as validating Stran's ability to address the complex marketing needs of its diversified customers. The expanded agreements, each representing six-figure expected annual revenue, are with multiple customers, including a best-in-class original equipment manufacturer serving the automotive industry, a state-of-the-art engineering products and services firm, and a leading global provider of mission-critical technologies and services for the oil and gas industry.

08:52 EDT LQR House acquires 8.58% stake in DRNK Beverage for $4.8M - LQR House announced the acquisition of 1,920,000 shares of DRNK Beverage Corporation at $2.50 per share, totaling $4.8M. The proceeds were irrevocably transferred for the sole and exclusive use of the issuer as of June 2024. This investment, which has been held in escrow, will not impact the cash on hand numbers reported in the Company's last filing. LQR House's investment in DRNK marks its strategic entry into both the non-alcoholic and ready-to-drink beverage markets, two rapidly growing sectors within the beverage industry. As consumers increasingly prioritize their health and wellness, there is a growing demand for drinks that offer functional benefits such as immune support, energy enhancement, added vitamins, probiotics, and plant-based ingredients. To meet this trend, DRNK has developed a ready-to-drink option with various nutritional advantages.

08:49 EDT HF Foods Group appoints Lisa Lim, Charlotte Westfall to board of directors - HF Foods Group announced the appointment of Lisa Lim and Charlotte Westfall to the Company's board of directors effective June 7, 2024. As a result of the appointments of Ms. Lim and Ms. Westfall, the Company's board of directors will now include four independent directors and Mr. Peter Zhang, the CEO of the Company. Lim is a retired partner with the global professional services organization, Ernst & Young. Westfall is a corporate partner based in the San Francisco office of a US global law firm

08:45 EDT Arcus completes enrollment for domvanalimab study for GI cancer - Arcus Biosciences (RCUS) announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences (GILD), evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. "STAR-221 completed enrollment well ahead of schedule, driven by significant interest from the global medical community in the potential for an anti-TIGIT-based regimen to address the high unmet need in this setting," said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Arcus Biosciences. "Domvanalimab is the first and only anti-TIGIT antibody to be studied in a Phase 3 trial in upper gastrointestinal adenocarcinoma. We are now preparing for the readout and look forward to the potential opportunity to make a meaningful difference for patients with this disease." ..Domvanalimab and zimberelimab are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of gastrointestinal cancers have not been established.

08:44 EDT Sellas Life Sciences announces initial data in Phase 2a trial of SLS009 - SELLAS Life Sciences Group announced the completion of enrollment as well as initial data from the ongoing Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. Thirty heavily pretreated patients were recruited in 5 centers across the US, reflecting the high unmet need of this refractory/relapsed patient population. Except for one, all patients in this Phase 2a trial had unfavorable/poor cytogenetic and/or molecular genetics risk and were treated with continued venetoclax - azacytidine combination therapy after having failed it or similar venetoclax combinations, often more than once. The expected overall survival in those patients is approximately 2.5 months. Key Highlights from the Initial Data: Safety: SLS009 was generally well-tolerated with no safety issues observed across all doses. There were no dose-limiting and no high-grade treatment-related non-hematologic toxicities. Hematologic toxicities profile was not different from that of venetoclax-based regimens alone. 27 patients had at least one efficacy assessment as of May 25, 2024, and were considered evaluable for efficacy. Efficacy: The overall response rate was 29.6% in all evaluable patients, and across all SLS009 doses, with the highest response rate of 50% observed at the dosing regimen of 30 mg BIW. In the first dose level of 45 mg once a week, the median overall survival among evaluable patients followed for survival was 5.4 months, compared to the expected survival of 2.5 months in patients refractory to and relapsed on standard venetoclax in combination with hypomethylating agents. In the second dose level, 60 mg, administered once a week, 3 out of 9 evaluable patients achieved an overall response defined as leukemia-free status that includes complete response, complete response with incomplete hematologic recovery, and morphologic leukemia-free state. Median survival has not been reached. In the third dose level of 30 mg twice a week, 4 out of 8 patients evaluable to date achieved overall response defined as leukemia-free status that includes complete response, complete response with incomplete hematologic recovery, and morphologic leukemia-free state. Median survival has not been reached. Observed efficacy outcomes exceeded the target ORR of 20% and mOS of 3 months. The highest response rates were observed among patients harboring ASXL1 mutations as previously reported. Notably, responses were highly correlated with mutational status, with 6 out of 8 responding patients having myelodysplasia-related somatic mutations and 5 having specifically ASXL1 mutations. A 100% overall response rate was achieved in patients with ASXL1 mutations in the 30 mg BIW cohort to date. Based on the preliminary findings from this Phase 2a trial, the trial has been expanded to include two additional cohorts consisting of dosing at 30 mg BIW. One cohort will enroll AML patients with ASXL1 mutations and the other AML patients with myelodysplasia-related molecular mutations other than ASXL1. Study enrollment continues and additional updates and data are expected in Q3.

08:40 EDT Rail Vision installs AI-driven system for class 1 U.S.A. operator - Rail Vision announced the successful installation of its AI-driven ShuntingYard product for a class 1 freight rail US-based company. The North American Class 1 rail company will use the system on its locomotive for evaluation in different scenarios related to safety and efficiency. This installation follows the purchase order, announced in March 2024, and is yet another step in the company's goal of enhancing the safety and efficiency of the American railway industry. The installed system integrates state-of-the-art technologies designed to provide real-time monitoring and obstacle detection, ensuring the highest standards of safety for rail operations, and is build to meet rigorous railroad demands, offering unparalleled reliability and performance.

08:39 EDT American Resources adjusts distribution date for special dividend - American Resources announced that, due to the Company's decision to list its wholly owned subsidiary, American Carbon Corporation, on a national exchange prior to its distribution, the Distribution Date for the previously announced special dividend has been adjusted to now occur on August 9, 2024. The special dividend of American Carbon Corporation will still be distributed to shareholders of record of American Resources as of May 27, 2024.

08:36 EDT RenovoRx appoints Ryan Witt as SVP, head of corporate strategy, partnerships - RenovoRx announced that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Witt, who has been a consultant to the Company for the past year, has a strong track record, backed by 15 years of experience, in successfully leading corporate strategy in both medical technology and biopharmaceutical companies.

08:36 EDT GeneDx announces collaboration with Epic Aura - GeneDx announced that it is expanding access to its rapid whole genome sequencing services in neonatal intensive care units with leading health systems through a new collaboration with Epic. The integration with Epic expands GeneDx's commercial strategy by connecting directly with health systems that use Epic's EHR to receive orders and send results. With more than 20 years of experience leading the industry in diagnosing children with rare diseases, including performing more than 80% of clinical exomes in the US today, GeneDx is increasing its focus to a rapidly growing segment of its business. GeneDx has seen an 80% year over year increase of its rapid testing business, and the payor landscape is rapidly evolving, with 11 states now offering Medicaid coverage and an increasing number of commercial payors adopting coverage policies for this critical testing. Patients will now have rWGS results seamlessly integrated into their single, comprehensive medical record, enabling providers to deliver more comprehensive patient care.

08:35 EDT Taoping reports May contract revenue up 52% y/y - Taoping reported a total contract revenue value of RMB 29.8M for the month of May 2024, representing an increase of 52% compared to the month of May 2023. This represents a 43% increase over April 2024, which had a total contract revenue value of RMB 20.8M. Led by growth of its cloud-based Smart City products and solutions, the addition of sales of the company's new AI-powered Smart Terminals was also an important driver of the surge in May contract revenue. The company anticipates that AI-based products will continue to expand and remain a key factor in driving revenue growth in 2024 and beyond.

08:35 EDT Cardio Diagnostics achieves SOC 2 Type I compliance certification - Cardio Diagnostics announced the successful completion of its System and Organization Controls, or SOC, 2 Type I audit, achieving compliance with the leading industry standards for customer data security.

08:34 EDT Actinium Pharmaceuticals reports results from Phase 3 SIERRA Trial of Iomab-B - Actinium Pharmaceuticals highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 - 11, 2024, in Toronto, Canada. The presentations featured results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients with active relapsed or refractory acute myeloid leukemia for a potentially curative bone marrow transplant. The Phase 3 SIERRA trial enrolled 153 r/r AML patients. Iomab-B achieved the primary endpoint of durable Complete Remission with high statistical significance. Additionally, Actinium's novel linker technology was highlighted in a presentation demonstrating high tumor uptake and in vivo stability in preclinical models with significantly lower kidney and liver uptake compared to standard DOTA linkers.

08:33 EDT Surrozen presents preliminary results from Phase 1a study of SZN-043 - Surrozen presented a poster on the preliminary results of a Phase 1a study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis on June 8, 2024 at the 2024 European Association for the Study of the Liver, EASL, in Milan. Study Overview: Safe and well-tolerated doses of SZN-043 were established in the randomized, placebo-controlled, first-in-human, Phase 1a trial in 40 healthy volunteers and 8 patients with a history of liver cirrhosis. Pharmacodynamic Biomarkers: The study provided evidence of Wnt-mediated pharmacodynamic activity in the liver after treatment with SZN-043. Target engagement was confirmed via transient increases in alkaline phosphatase. Increases in ALP are indicative of SZN-043 binding to, and elimination of, its targeting receptor asialoglycoprotein from the surface of the hepatocytes and this reduction in its capacity to clear ALP is consistent with observations in other ASGPR binding agents. Wnt signal activation was demonstrated by the results of the methacetin breath test. This test showed increased methacetin clearance following SZN-043 administration which is indicative of activation of the Wnt target gene, CYP1A2, in hepatocytes. HepQuant measurements demonstrated increases in the portal hepatic filtration rate. The HepQuant test is a quantitative liver function test that measures cholate clearance to assess liver function. The increase in portal HFR is thought to be related to Wnt-mediated induction of cholate clearance by SZN-043.

08:32 EDT Cuentas provides update on partnership with World Mobile Group - Cuentas announces an update on its partnership with World Mobile Group. This newly launched joint program offers an immediate internet access alternative to 23 million households in the United States, following the termination of the Affordable Connectivity Program on June 1, 2024. Cuentas is set to launch this initiative leveraging World Mobile's innovative platform, deploying localized networks tailored to specific customer needs. This seamless integration will provide internet access, roaming services, and mobile solutions, with a nationwide rollout expected as soon as July 2024. The Affordable Connectivity Program, canceled by the Federal Communications Commission effective June 1, 2024, due to lack of additional funding from Congress, previously enabled households to afford essential broadband for work, school, healthcare, and more. The ACP benefit provided a discount of up to $30 per month for internet service for eligible households and up to $75 per month for those on qualifying Tribal lands. Cuentas and World Mobile will promote this alternative service through a network of 30,000 retail outlets across the United States, currently served by CUEN's mobile and fintech offerings.

08:23 EDT Royal Bank of Canada to repurchase up to 30M of common shares - Royal Bank of Canada announced that the Toronto Stock Exchange and the Office of the Superintendent of Financial Institutions have approved its normal course issuer bid to purchase, for cancellation, up to 30M of its common shares. Purchases under the normal course issuer bid may commence on June 12, 2024 and continue until June 11, 2025, when the bid expires, or such earlier date as the Bank may complete its purchases pursuant to the notice of intention filed with the TSX.

08:19 EDT 1847 Holdings reports 'continued progress' on pending transactions - Ellery W. Roberts, CEO of 1847 Holdings, commented, "We remain on track with several potentially transformative strategic transactions. Specifically, we are nearing completion of a definitive agreement to acquire a prominent millwork, cabinetry, and door manufacturer. This target achieved revenues of $28.6 million and significant cash flow in 2023. Moreover, as previously disclosed, we negotiated a favorable purchase price of $16.75 million, which represents approximately 3.2x the target's 2023 EBITDA. We are also engaged in active discussions with several parties interested in acquiring one of our business lines and we are encouraged by the progress. In parallel, we are actively working on restructuring and accelerating the repayment of our debt. This includes extending the duration of remaining indebtedness and eliminating any equity-linked aspects of repayment. We believe these actions would create a more favorable capital structure for the Company and our shareholders, positioning us for sustained long-term success. We are highly confident that these and other strategic initiatives will drive significant value for our shareholders as we continue to execute our growth strategy. We look forward to providing further updates as these transactions continue to progress," concluded Mr. Roberts.

08:17 EDT Revolve Renewable receives $3.4M milestone payment - Revolve Renewable Power announce the completion of the interconnection milestone related to the 1,000MW Bouse Solar and Storage Project, which was sold in January 2023 to ENGIE IR Holdings LLC, a wholly-owned subsidiary of ENGIE. The terms of the sale, which also included the sale of the 250MW Parker Solar & Storage Project, are set out in the news release dated January 11, 2023. The total consideration payable by ENGIE is within the range of guidance previously provided by the Company for the sale of utility scale development assets. The Company received an upfront payment of US$2,000,000 on completion of the transaction in January 2023. Of this sum, US$800,000 was recognised as revenue in the Company's Q3 FY2023 financial accounts with the remaining US$1,200,000 accounted for as deferred revenue. The balance of this deferred revenue as at March 31, 2024 was US$960,000. The remaining consideration is linked to each of the Parker Project and Bouse Project successfully completing the following development milestones: Completion of further interconnection studies; Issuance by ENGIE of a Notice To Proceed construction works to the applicable Engineering and Procurement Contractor. On the Commercial Operations Date, with such date being the date that a project has been synchronized to the grid and is capable of delivering all of its installed capacity to the grid. The Company previously guided that it expected the completion of the interconnection studies milestones for the Bouse Project to be achieved prior to the end of H1 2024 when further interconnection studies are issued. We are now pleased to confirm that the completion of further interconnection studies milestone has been met for the Bouse Project. As part of the transaction the parties entered into a put option agreement allowing ENGIE to sell the Bouse Project back to the Company for a limited period following receipt of the results of the next interconnection studies due for each project. ENGIE has chosen not to exercise the Put Option and it has therefore expired for the Bouse Project. The next milestone payment related to the Bouse Project totalling US$3,400,000 has now been paid to the Company. There were no additional development costs incurred by the Company in relation to this milestone. The deferred revenue of US$960,000 is now expected to be recognised as revenue in the Company's Q4 FY2024 financial statements.

08:16 EDT Oceaneering in $120M-$183M manufactured products contracts with Petrobras - Oceaneering International (OII) announced that its Manufactured Products segment has secured two significant contracts with Petrobras (PBR) through a competitive bidding process. The expected aggregate net revenue is in the range of $120M to $183M. Oceaneering is contracted to supply up to 362 kilometers, or approximately 225 miles, of steel tube and thermoplastic electro-hydraulic umbilicals and associated subsea distribution hardware for use in projects offshore Brazil. Manufacturing of the products is scheduled to take place at Oceaneering's Niteroi, Brazil facility with the final delivery expected in the fourth quarter of 2027. Reflecting on these achievements, Roderick A. Larson, President and Chief Executive Officer of Oceaneering, stated, "The award of these major contracts reinforces our confidence in the durability and commitment of our customers to the resurgent deepwater markets. It further demonstrates Oceaneering's position as a trusted provider with the ability to deliver quality work in a safe and timely manner. This advances the leading-edge position of our Brazilian manufacturing operation and we look forward to supporting Petrobras on these projects."

08:14 EDT Maris-Tech receives repeat order for $957,000 from defense industry company - Maris-Tech has received a repeat order of approximately $957,000 for a customized solution that provides armored and autonomous vehicles with enhanced situational awareness. This is the third order for this unique solution from the same customer, and it is expected to be delivered by the end of 2024.

08:13 EDT Murano Global Investments explores cruise port development in Mexico - Murano Global Investments announced that it has signed a non-binding memorandum of understanding with a leading global cruise operator to explore the potential to develop a cruise port destination on its property in Bajamar, Baja California, Mexico. The Baja Project is situated on the Tijuana Ensenada corridor, 60 minutes from the Tijuana/San Diego border and a few minutes from the beaches of Ensenada, Tijuana and Rosarito. Elias Sacal, CEO of Murano commented, "We are delighted to have engaged with a world leader in the cruise lines industry, as we seek to create a new major tourist destination with the proposed cruise port in our Baja Project. Importantly, there are no other cruise ports in proximity to our location. This would make the development of a port a highly strategic and mutually beneficial endeavor for Murano, the cruise operator and the local economy, which would benefit significantly from enhanced tourism. We strongly believe that Murano has the vision, know-how and experience to launch major developments and create world-class destinations, and that this development will again demonstrate these capabilities."

08:11 EDT Aeries Technology announces strategic partnership with Victory Live - Aeries Technology announced its strategic partnership with Victory Live, a global technology platform focused on sports and entertainment, event management, data, and ticketing software and solutions founded by industry veteran Sam Soni and backed by Clearlake Capital Group. This collaboration marks the beginning of a strategic initiative, including the establishment of an innovative Global Capability Center for engineering roles in Hyderabad, India. Victory Live's Chief Technology Officer Sathish Gaddipati explained: "The launch of the Global Capability Center in Hyderabad, in partnership with Aeries Technology, represents a strategic leap forward for Victory Live. This GCC is more than a geographic expansion. It represents our commitment to leveraging global technology talent and optimizing operational efficiencies. By bringing together diverse teams from across the globe, we are setting new standards in the ticketing industry and redefining what is possible through collaboration and innovation."

08:11 EDT SPX Technologies appoints Johnson as Chief Legal Officer - SPX Technologies (SPXC) announces the appointment of Cheree Johnson as its new Chief Legal Officer and Secretary, effective June 10, 2024. She succeeds John Nurkin, who earlier this year announced his decision to retire. Johnson has over 20 years of senior executive experience. Johnson joins SPX from Dentsply Sirona (XRAY) where, as the senior vice president, Chief Legal Officer, General Counsel & Secretary.

08:09 EDT AgriFORCE Growing Systems granted new U.S. patent - AgriFORCE Growing Systems announces the granting of U.S. Patent B2, titled, "Automated Growing Systems" by the United States Patent and Trademark Office, USPTO. The patent adds to the Company's intellectual property portfolio connected to agriculture and agribusiness. The patent, which covers moving multiple production lines of either vegetation or flowering plants to different areas of a growing facility using conveyor belts and other mechanisms. The Company believes there are opportunities to incorporate this technology into their existing innovations for indoor growing facilities.

08:08 EDT Addus HomeCare to acquire personal care operations of Gentiva for $350M - Addus HomeCare announced a definitive agreement to acquire the personal care operations of Gentiva for an anticipated purchase price, after customary purchase price adjustments, of approximately $350M. Based in Atlanta, Georgia, Gentiva is a dedicated hospice, palliative, and personal care services company and the transaction relates only to its personal care operations, which serve over 16,000 patients per day in a seven-state service area of Arizona, Arkansas, California, Missouri, North Carolina, Tennessee and Texas. Addus expects to close the transaction following completion of regulatory approvals and subject to customary closing conditions. Addus will fund the acquisition through the company's existing revolving credit facility. BofA Securities, Inc. is serving as an exclusive financial advisor and Bass Berry & Sims PLC is serving as legal counsel to Addus in this transaction. Goldman Sachs & Co. LLC is serving as financial advisor and Debevoise & Plimpton LLP and Ropes & Gray LLP are serving as legal counsel to Gentiva.

08:07 EDT Fortinet to acquire Lacework, terms not disclosed - Fortinet has entered into a definitive agreement to acquire Lacework, the data-driven cloud security company. Lacework delivers a leading AI-powered cloud security platform that seamlessly integrates all critical CNAPP services. With patented AI and machine learning technology, an agent and agentless architecture for data collection, a homegrown data lake, and a powerful code security offering, Lacework is trusted by nearly 1,000 customers to deliver comprehensive security from code to cloud. Fortinet intends to integrate Lacework's CNAPP solution into Fortinet's Unified SASE offering, forming one of the most comprehensive, full stack AI-driven cloud security platforms available from a single vendor. This will help customers identify, prioritize, and remediate risks and threats in complex cloud-native infrastructure from code to cloud. This strategic acquisition aligns with Fortinet's growth strategy in the Unified SASE market, which includes solutions for securing access and cloud, and underscores the company's commitment to innovation and integration. As part of the acquisition, Fortinet is committed to a seamless transition for Lacework customers and partners. Backed by Fortinet's proven leadership and expertise, Lacework customers will be able to benefit from access to Fortinet's global reach, extensive scale, vast resources, and industry-leading threat intelligence while continuing to leverage their existing security infrastructure investments. Financial terms of the transaction were not disclosed. The transaction, which is expected to close in the second half of 2024, is subject to required regulatory approvals and other customary closing conditions.

08:07 EDT Sunnova Energy CFO Robert Lane departs, Eric Williams succeeds - Sunnova Energy announced that Eric Williams has been appointed executive VP, CFO, effective June 10. Williams is a seasoned finance executive with more than 20 years of experience across multiple industries. He has worked in the energy industry for the past 13 years of his career, most recently as CFO and executive VP of Diversified Energy Company. During his tenure with Diversified, Williams established the company's asset backed securitization structure and, in total, led the issuance of approximately $2B in securitized debt. Williams will replace Robert Lane, who served as Sunnova's executive VP, CFO from May 2019 to June.

08:06 EDT ABM, Rezcomm collaborate to enhance ABM Vantage platform - ABM has announced the next evolution of ABM Vantage. ABM has entered into a strategic partnership with Rezcomm to further customize, enhance, and scale the ABM Vantage platform for a wider range of parking clients across commercial real estate, aviation, and more. ABM and Rezcomm will showcase the enhanced ABM Vantage collaboration at the 2024 IPMI Parking & Mobility Expo on June 9th to 12th in Columbus, OH. First launched in 2022, ABM Vantage is an integrated mobility solution that consolidates parking data, maximizes revenue, and empowers parking operations to gain greater efficiencies and make proactive decisions based on data insights, all while delivering a seamless driver experience. The partnership with Rezcomm will support further growth with increased ability to scale quickly, while remaining tech agnostic and focused on the changing needs of both drivers and parking operators

08:05 EDT Assembly Biosciences doses first participant in Phase 1a/b trial of ABI-5366 - Assembly Biosciences announced that the first participant has been dosed in the Phase 1a/b trial of its long-acting herpes simplex virus, HSV, helicase-primase inhibitor candidate ABI-5366. "We are pleased to advance ABI-5366 into clinical development for recurrent genital herpes, a disease which significantly impacts the lives of millions of people, and where no new therapeutic options have been approved in over 25 years," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "Importantly, since the HSV helicase-primase is a clinically validated viral target, the PK data from healthy participants in the Phase 1a part of this study will enable us to assess the ability of ABI-5366 to achieve the target concentrations we have established for antiviral efficacy and to support a once-weekly oral dosing profile. These data will also inform our dose selection for the multiple ascending dose Phase 1b part of the study, where we will evaluate viral and clinical outcomes in individuals with recurrent genital herpes."

08:04 EDT Conduent to repurchase all shares held by Carl Icahn for $132M - Conduent announced that it entered into and consummated a share purchase agreement to repurchase all of the shares of the company's common stock beneficially owned by Carl Icahn through certain of his affiliates at a purchase price of $3.47 per share, the closing price of the company's common shares on June 7, the last full trading day prior to the execution of the purchase agreement. The aggregate purchase price for the repurchase is approximately $132M, which was funded from Conduent's cash on hand and existing credit facility. Following the purchase, the Icahn parties no longer hold any Conduent common shares. In connection with the transaction, Hunter Gary, Jesse Lynn and Steven Miller, who are employed by the Icahn Parties, have resigned from the company's board of directors. The transaction was unanimously recommended to Conduent's board by a special transaction committee of the board, comprised solely of independent directors. The special transaction committee was advised by independent legal and financial advisors. The entire board, except for members employed by Icahn Parties, who recused themselves from the vote, voted in favor of the transaction.

08:04 EDT Monopar Therapeutics presents data showcasing appeal of uPAR - Monopar Therapeutics is presenting data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging, SNMMI, Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar's poster highlights the potential promise of both the urokinase plasminogen activator receptor as a radiopharma cancer target for solid tumors as well as MNPR-101 as a targeting agent against uPAR. The data presented demonstrate robust, durable tumor uptake of Zr-89 radiolabeled MNPR-101 in human tumor xenograft mouse models of triple-negative breast, colorectal, and pancreatic cancers. Monopar's optimization of the MNPR-101-Zr construct achieved markedly higher tumor uptake and drug stability while minimizing accumulation in bone and healthy tissue.

08:03 EDT Abbott receives FDA approval for two new OTC CGM systems - Abbott announced U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems - Lingo and Libre Rio, which are based on Abbott's world-leading FreeStyle Libre continuous glucose monitoring technology, now used by about 6M people globally. The newly cleared systems have been intentionally designed to meet different needs - Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

08:03 EDT Oxbridge Re Holdings to evaluate strategic alternatives - Oxbridge Re Holdings announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. As part of the evaluation process, the Company will consider a full range of strategic alternatives for the Company, and/or its Web-3 division subsidiary SurancePlus Holdings Ltd, including a sale, spinout, merger, divestiture, recapitalization, and other strategic transactions, or continuing to operate as a public, independent company. The Company cannot assure that its evaluation will result in the Company and/or its subsidiaries pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. The Board has not set a timetable for the conclusion of this review. There can be no assurance that the review will result in any transaction or other strategic change or outcome. The Company does not intend to comment further until it determines that further disclosure is appropriate or necessary.

08:00 EDT Enhabit files definitive proxy materials and mails letter to stockholders - Enhabit announced that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming 2024 annual meeting of stockholders scheduled for July 25, 2024. Stockholders of record as of the close of business on June are entitled to vote at the 2024 Annual Meeting. In connection with the filing of its definitive proxy statement, Enhabit is mailing a letter to stockholders. Enhabit's definitive proxy materials and other materials regarding the Board of Directors' recommendation for the 2024 Annual Meeting can be found at investors.ehab.com. Dear Fellow Stockholder, "At our upcoming 2024 Annual Meeting of Stockholders you will have an important decision to make about the future of Enhabit Home Health & Hospice - whether our Board should be replaced and control of Enhabit handed to one of our stockholders, AREX Capital Management . Your current Board unanimously believes the answer to this question is emphatically, no. Allow us to explain. Previously a subsidiary of Encompass Health Corporation Enhabit has been a public company for just seven full quarters. Neither our financial results nor our stock performance has satisfied expectations during this period and certainly have not met the standard your Board has set for Enhabit. This is due to a variety of factors, including the structure and condition of our Company at the time of the spin-off, as well as industry headwinds that were exacerbated due to our business mix. We also experienced a few operational missteps, which did not meet the high standards we have set for ourselves."

07:54 EDT Vista Outdoor receives $2.01B alternative offer for The Kinetic Group - Vista Outdoor confirmed that it received an indication of interest from a U.S. based private investment firm, which was involved in the prior sales process for The Kinetic Group in 2023, pursuant to which the alternative party would acquire The Kinetic Group for $2.01B in cash, on a cash-free, debt-free basis. The $47.75M break fee payable to Czechoslovak Group in the event that Vista Outdoor determined to terminate the merger agreement with CSG and enter into a transaction with the alternative party would be payable by Vista Outdoor. The alternative party stated that it would commit to fully supporting the purchase price and is prepared to execute definitive agreements no later than June 14. The board of directors has determined the indication of interest from the alternative party would reasonably be expected to lead to a superior proposal and meets the standard for engagement under the terms of the CSG merger agreement. The company remains bound by the terms of the merger agreement with CSG, and the Vista Outdoor Board continues to recommend the acquisition of The Kinetic Group by CSG. In addition, Vista Outdoor continues to be confident that it will receive clearance from the Committee on Foreign Investment in the United States, or CFIUS, with respect to the proposed transaction with CSG and that all other closing conditions will be satisfied. There can be no assurance that the Vista Outdoor Board will ultimately determine that the indication of interest from the alternative party is a superior proposal, that the terms of a transaction with the alternative party will be the same as those reflected in its indication of interest or that any transaction with the alternative party will be agreed to or consummated.

07:41 EDT Virtu announces proposed private offering of $500M Senior First Lien Notes - Virtu Financial announced that its subsidiaries, VFH Parent and Valor Co-Issuer, intend to offer $500 million aggregate principal amount of senior first lien notes due 2031 in an opportunistic private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The notes will be fully and unconditionally guaranteed on a senior secured first-lien basis by Virtu Financial and each of Virtu Financial's existing and future wholly owned domestic subsidiaries that guarantee, or are borrowers under, the Issuer's senior secured first lien credit facilities. The Offering remains subject to market and other customary conditions. The Issuers intend to use the proceeds of the Offering to repay $500 million aggregate principal amount outstanding under the Issuer's existing senior secured first lien term loan facility. Concurrently with the consummation of the Offering, the Issuer intends to amend its existing credit agreement to provide for a $1,245 million senior secured first lien term loan facility, increase the commitments under its existing senior secured first lien revolving credit facility to $300 million and extend the maturity thereof and amend certain other provisions of its existing credit agreement. If the closing of the amended credit facilities is successfully consummated, the Issuer intends to use the proceeds from the new term loan facility to repay all remaining amounts outstanding under the existing term loan facility. The Issuer intends to use cash on hand to pay discounts, fees, commissions and expenses of the Offering, the closing of the amended credit facilities and the refinancing of the existing term loan facility. The closing of the amended credit facilities remains subject to market and other customary conditions. The consummation of the Offering is not contingent upon the closing of the amended credit facilities. The closing of the amended credit facilities is not contingent upon the consummation of the Offering.

07:38 EDT Vitalhub acquires Premier I.T. Partnership for initial cash payment of GBP 2.17M - VitalHub has acquired Premier I.T. Partnership Limited, a company incorporated and existing under the laws of England and Wales. Premier IT offers workforce planning, development and performance solutions for the healthcare sector that optimizes the deployment of resources, improves transparency and fairness, and ensures that staff can spend more time safely and confidently doing the things that matter. These solutions encompass appraisal and revalidation needs for doctors and nurses, multi-source feedback, e-rostering, job planning, and healthcare compliant learning management systems solutions. Premier IT proudly provides these services to over 125 customer organizations empowering thousands of daily users in the United Kingdom. VitalHub acquired Premier IT from its shareholders for a cash payment of GBP 2,166,718, with an additional opportunity to earn up to GBP 472,849 over the course of two years post Acquisition by achieving specific financial milestones. A portion of the proceeds will be held in escrow following closing of the Acquisition. As of the Acquisition, Premier IT had estimated annualized contracted revenues of GBP 1,300,000 of which substantially all were identified to be recurring in nature from its wide-ranging customer base, which underscores the Acquisition's strategic fit within VitalHub's portfolio.

07:37 EDT Revive provides update from FDA meeting for Long COVID diagnostic product - Revive Therapeutics announced an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration, FDA, of the Revive LC POC Lateral Flow Test Kit for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions. The FDA has determined that the Product should follow the De Novo regulatory pathway, and the Company would be required to conduct a clinical study for the De Novo submission for possible approval. "We agree with the FDA feedback and with their recommendations that provides a pathway for the development of the Revive LC POC Lateral Flow Test Kit in the detection of long COVID," said Michael Frank, CEO of Revive. "We will now discuss the proposed development plan and timelines with potential contract manufacturers."

07:37 EDT Ayr Wellness secures real estate financing for Florida indoor cultivation - AYR Wellness (AYRWF) announced the closing of a triple-net lease transaction with Innovative Industrial Properties (IIPR) in the State of Florida. Under the terms of the agreement, AYR is leasing a 16-acre property comprising of 145,000 square feet of industrial space in Ocala, Florida from IIP. AYR plans to redevelop a 98,000 square foot building within the property to serve as a regulated cannabis cultivation facility. IIP has committed to funding AYR up to $30.0 million for the construction.

07:36 EDT Orezone Gold appoints Sean Harvey as board chair - Orezone Gold Corporation reports that all resolutions from the Company's annual general and special meeting of shareholders held on June 7, 2024 were approved with 61.45% of the total issued and outstanding shares of the Company represented at the Meeting. Following the Meeting, the directors of the Company appointed Mr. Sean Harvey as Chair of the board of directors. Additional matters approved at the Meeting are as follows: The number of directors was fixed at eight. The amendment to increase the number of common shares reserved under the Company's Restricted Share Unit Plan by 7,500,000 common shares for a total of 15,000,000 common shares was approved. The amendment to increase the number of common shares reserved under the Company's Deferred Share Unit Plan by 2,500,000 common shares for a total of 5,000,000 common shares was approved. The Advance Notice By-Law was ratified and approved. Deloitte LLP was appointed as auditors for the fiscal year ending December 31, 2024, and the board of directors was authorized to fix their remuneration.

07:35 EDT Inotiv provides business updates - Inotiv provided the following business updates: Hillcrest, U.K. expansion project completed; Extension of the maturity date of the $3.7 million OBRC payable note to July 2025. Robert Leasure Jr., President and Chief Executive Officer, commented, "We have substantially completed the Hillcrest, U.K. expansion and improvements, which allows for two new customers with long term contracts, to begin occupying their new space at this facility and for the transfer of our Blackthorn, U.K. operations into Hillcrest. The Hillcrest project has been another significant part of our transformation plan which we initiated in 2022. The transformation has included multiple site closures, significant investments in remaining facilities to support growth, and included investments in infrastructure, animal welfare and safety improvements."

07:34 EDT Twelve Seas Investment Company II announces plan to liquidate - Twelve Seas Investment Company II announced that its board of directors has determined not to implement the extension of the date by which the Company must consummate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses from June 2, 2024 to December 2, 2024, or such earlier date as determined by the Board that was approved on May 28, 2024 at a special meeting of stockholders and it intends to liquidate the Company instead. The Board made these determinations based on its belief that the Company would be unable to consummate a Business Combination by August 26, 2024, the deadline provided by the Nasdaq Stock Market LLC Hearings Panel following a hearing held on May 2, 2024 regarding the Company's non-compliance with Nasdaq Listing Rule IM-5101-2 and Nasdaq Listing Rule 5250(c)(1). Consequently, all shares submitted by stockholders for redemption in connection with the Meeting are being returned to such redeeming stockholders per the terms of the Third Extension as set forth in the Company's Definitive Preliminary Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 14, 2024. On June 4, 2024, the Company notified the Panel of its decision to withdraw from the hearings process and on June 6, 2024, the Company received confirmation from the staff of the Listing Qualifications Department of Nasdaq about the withdrawal decision. As a result of the Company withdrawing its appeal, its public securities will be suspended from trading on the Nasdaq Capital Market at the open of business on June 10, 2024. The Company's public securities will then begin trading on the over-the-counter market on June 10, 2024, under the same trading symbols, "TWLV", TWLVU" and "TWLVW". On June 4, 2024, the Board also determined that it is in the best interests of the Company's stockholders for the Company to not utilize the Third Extension and instead to cease all operations except for the purpose of winding up as soon as practicable, as promptly as reasonably possible redeem the shares of Class A common stock that were included in the units issued in the Company's initial public offering at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account established in connection with the IPO including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes divided by the number of outstanding Public Shares, which redemption will completely extinguish public stockholders' rights as stockholders, subject to applicable law, and as promptly as reasonably possible following the Redemption, subject to the approval of the Company's remaining stockholders and its Board, liquidate the funds held in the Trust Account and dissolve the Company, subject in each case to its obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. Twelve Seas Sponsor II LLC, the Company's sponsor, has agreed to waive its redemption rights with respect to the shares of Class B common stock of the Company issued prior to the IPO and shares of the Company's Class A common stock issued upon conversion of the Class B common stock. In order to provide for the disbursement of funds from the Trust Account, the Company has instructed Continental Stock Transfer & Trust Company, as its trustee, to take all necessary actions to effect the Liquidation. The proceeds thereof, less $100,000 of interest to pay dissolution expenses and net of taxes payable, will be held in a trust operating account while awaiting disbursement to the holders of the Public Shares. The Company expects to redeem all of the outstanding Public Shares for an estimated redemption price of approximately $10.558 per share which amount reflects the payment of up to $100,000 of dissolution expenses and the payment of taxes. All other costs and expenses associated with implementing the Dissolution will be funded from proceeds held outside of the Trust Account. Record holders of Public Shares will receive their pro rata portion of the proceeds of the Trust Account by delivering their Public Shares to Continental, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the Redemption Amount. The Redemption Amount is expected to be paid out within ten business days after the instruction to Continental to commence the Redemption and Liquidation.

07:33 EDT Booz Allen acquires PGSC from Par Technology, terms undisclosed - Booz Allen (BAH) announced that it has acquired PAR Government Systems Corporation, or PGSC, a wholly owned subsidiary of PAR Technology (PAR). The acquisition will combine PGSC's edge technologies with Booz Allen's mission expertise and digital battlespace solutions to accelerate and transform warfighter technology on the front lines. Founded in 1985 and headquartered in Rome, New York, PGSC delivers differentiated services and solutions in strategic mission areas, including the provision of real-time communications and mobile situational awareness to maintain battlespace dominance. PGSC will integrate into Booz Allen's global defense business led by Sector President Judi Dotson.

07:32 EDT Brainsway launches trial evaluating accelerated Deep TMS for depression - BrainsWay announced the initiation of a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company's proprietary Deep Transcranial Magnetic Stimulation, Deep TMS, system to treat major depressive disorder. The clinical trial is anticipated to enroll over 100 patients with major depressive disorder who will be split into two groups - one receiving a novel accelerated treatment protocol featuring an acute phase over several treatment days, and the other receiving the FDA-cleared standard-of-care protocol which entails an acute phase over several weeks. The design of this non-inferiority trial, which was determined in discussion with the U.S. Food and Drug Administration, aims to compare the outcomes achieved with the accelerated Deep TMS protocol versus the current standard-of-care Deep TMS protocol.

07:31 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on June 6, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

07:29 EDT IRB approves Can-Fite's study of efficacy of Namodenoson in treatment of PC - Can-Fite BioPharma announced that it received an approval from the Institutional Review Board IRB of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted. The approved protocol has been submitted now to the Ministry of Health MOH ."This Phase IIa study is designed as an open-label one, enabling us to assess the safety and potential efficacy of Namodenoson in pancreatic cancer patients whose disease has progressed despite first-line treatment...Pathway" for a poster presentation at the AACR Special Conference on Pancreatic Cancer, and from Biomolecules, a scientific journal focused on the function and mechanism of bioactive molecules, which published an article titled "Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/ss-catenin, NF-?B, and RAS Signaling Pathways."

07:22 EDT Northern Dynasty files motion to modify EPA complaint by adding new claims - Northern Dynasty and 100%-owned U.S.-based subsidiary Pebble Partnership have filed a motion for leave to file an amended complaint in the federal district court in Alaska to reverse the U.S. Army Corps, or USACE, decision to deny the project a permit. Ron Thiessen, President and CEO of Northern Dynasty, said "It is important to understand that this is not a new lawsuit. It is simply an amendment of the complaint we filed against the Environmental Protection Agency ("EPA") by adding the USACE as another defendant. We think this substantially strengthens the existing case by focusing directly on the permit denial which was an underlying reason for the EPA veto."

07:16 EDT American Oncology Network commences OTCQX trading - American Oncology Network announced it has qualified to trade on the OTCQX Best Market. AON previously traded on NASDAQ.

07:14 EDT SolarEdge CFO Ronen Faier to step down, Ariel Porat to succeed - SolarEdge announced the appointment of Ariel Porat as senior VP, finance. The appointment comes as part of a succession plan for the CFO role at the company. Ronen Faier, who currently serves as the company's CFO, has notified the board of directors of his desire to step down from the CFO role. Faier will continue to serve as the company's CFO for approximately three months at which time and upon the board's formal appointment, Porat is expected to assume the role of CFO of the company. Faier is expected to remain with the company to assist with the transition and work on other strategic projects.

07:13 EDT Aya Gold & Silver added to the S&P/TSX Composite Index - Aya Gold & Silver announced that its common shares will be added to the S&P/TSX Composite Index effective prior to the open of trading on June 24, 2024.

07:10 EDT Creative Realities appoints Schultz as VP, New Business Development - Creative Realities announces the appointment of David Schultz as Vice President, VP, New Business Development, to its leadership team. Schultz brings over 25 years of experience in sales and business development, having held leadership roles at notable companies, most recently with Stratacache.

07:09 EDT Osisko Development amends $50M credit facility - Osisko Development entered into an amending agreement to the credit agreement with National Bank of Canada made as of March 1, 2024 providing for a $50 million delayed draw term loan, through its wholly-owned subsidiary, Barkerville Gold Mines. The Amendment provides for, among other things: An 8-month extension to the maturity date of the Credit Facility to October 31, 2025. The extension is subject to the Company completing a capital raise of at least $20 million prior to October 31, 2024, otherwise the maturity date reverts to February 28, 2025. Reduction in the mandatory prepayment amount to 50% of each incremental dollar raised in excess of $25 million in respect of certain financings, allowing the Company to preserve 50% of such proceeds. There are no mandatory prepayment requirements for amounts up to $25 million. There are no other material changes to the term of the Credit Facility.

07:07 EDT FDA grants priority review to AstraZeneca's Tagrisso for EGFRm NSLC - AstraZeneca's supplemental New Drug Application or sNDA for TAGRISSO or osimertinib, has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated EGFRm non-small cell lung cancer NSCLC after chemoradiotherapy CRT . If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 mutations...Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "Priority Review of TAGRISSO in this early-stage curative setting is important for patients who currently have no targeted treatments available. We look forward to close collaboration with the FDA on an accelerated path to bring TAGRISSO to patients as a potential new standard of care as quickly as possible. TAGRISSO continues to serve patients as a backbone therapy in EGFR-mutated lung cancer, extending progression-free survival in the LAURA trial by more than three years and reinforcing the importance of testing for EGFR mutations at the time of diagnosis."

07:06 EDT Sonoco Products implements $70 per ton increase of URB in the U.S., Canada - Sonoco announced it is implementing a $70 per ton price increase for all grades of uncoated recycled paperboard, URB, in the United States and Canada, effective with shipments beginning July 10, 2024. This price action is necessary to offset increased input costs.

07:05 EDT Transcode Therapeutics regains compliance with Nasdaq listing requirements - TransCode Therapeutics announced that it has received notice from the NASDAQ Stock Market that the Company has regained compliance with all applicable Nasdaq listing standards. As a result, the Company's stock will remain listed and traded on the Nasdaq Stock Market. The Company's hearing before the Nasdaq Hearing Panel scheduled for June 25, 2024, has been cancelled. As previously disclosed, the Company remains subject to a mandatory Nasdaq panel monitor through January 26, 2025.

07:05 EDT C4 Therapeutics appoints Cooper as Chairman of Board of Directors - C4 Therapeutics announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharmaceutical executive experienced across discovery, development and commercialization, has been appointed chairman of C4T's Board of Directors. Bruce Downey, who served as chairman between June 2022 and June 2024, remains a member of the Board of Directors. As part of C4T's continued Board evolution with this appointment, Glenn Dubin, who has served on C4T's Board of Directors since 2021, has decided to step down from the Board of Directors. Ron Cooper most recently served as president and chief executive officer of Albireo Pharma/

07:05 EDT Surmodics awarded thrombectomy products agreement with Premier - Surmodics announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce and Pounce Venous Thrombectomy Systems.

07:03 EDT Skye Bioscience to discontinue clinical development related to SBI-100 OE - "The results of this Phase 2a clinical trial of SBI-100 OE unfortunately did not meet our pre-set criteria for continuation and further development of this molecule as an alternative treatment for glaucoma and ocular hypertension. We will continue to evaluate the full data set and intend to publish findings," said Tu Diep, Skye's Chief Development Officer. "We thank the patients and investigators who supported our clinical investigation of SBI-100 OE in this study."

07:03 EDT Cognizant to acquire Belcan for approximately $1.3B in cash and stock - Cognizant announced it has signed a definitive agreement to acquire Belcan, a portfolio company of AE Industrial Partners and a leading global supplier of Engineering Research & Development services, at a purchase price of approximately $1.3B in cash and stock, subject to customary adjustments. Belcan is an established player in ER&D that provides mission-critical digital engineering services for a long-standing customer base across the commercial aerospace, defense, space, marine and industrial verticals, primarily in North America and the United Kingdom. The revenue the acquired business will contribute to Cognizant in 2024 depends on the timing of the close but is expected to be over $800M on an annualized basis. Revenue from the acquired business has grown at an 8% compound annual growth rate over the last two years. The transaction is anticipated to close in the quarter ending September 30th, 2024, subject to the receipt of required regulatory approvals and other closing conditions. The total purchase price of approximately $1.29B, subject to customary adjustments, comprises $1.19B in cash consideration and a fixed 1.47M Cognizant shares, with a current value of $97M based on Cognizant's closing share price on Friday, June 7, 2024. The cash consideration is expected to be funded through a mix of cash on hand and debt. Cognizant intends to increase its share repurchase plan to maintain current share count guidance of 497M for the full year 2024.

07:02 EDT Centessa appoints Crowley as CFO, Weinhoff as CBO - Centessa Pharmaceuticals announced that John Crowley CPA, has been appointed Chief Financial Officer, CFO, and Gregory Weinhoff, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, CBO, effective June 10, 2024. Crowley most recently served as Chief Financial Officer of Fusion Pharmaceuticals. Weinhoff served as Chief Financial Officer of Centessa from March 2021 to June 2024.

07:00 EDT Moderna announces mRNA-1083 trial meets primary endpoints - Moderna announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial. mRNA-1083 comprises components of mRNA-1010, Moderna's vaccine candidate for seasonal influenza, and mRNA-1283, Moderna's next-generation COVID-19 vaccine candidate. Each investigational vaccine has independently demonstrated positive Phase 3 clinical trial results. The ongoing Phase 3 clinical trial is a randomized, observer-blind, active control study evaluating the safety, reactogenicity and immunogenicity of mRNA-1083 in two independent age group cohorts of approximately 4,000 adults each. One cohort, consisting of adults 65 years and older, compared mRNA-1083 to co-administered Fluzone HD, an enhanced influenza vaccine, and Spikevax, Moderna's currently licensed COVID-19 vaccine. The other cohort of adults 50 to 64 years of age compared mRNA-1083 to co-administered, Fluarix(R), a standard dose influenza vaccine, and Spikevax. The immune responses from a single dose of mRNA-1083 were found to be non-inferior versus the co-administered, routinely recommended, licensed comparators. In both age cohorts, mRNA-1083 also elicited statistically significantly higher immune responses against three influenza virus strains and against SARS-CoV-2. In the 65 years and older cohort, overall Geometric Mean Ratios, or GMRs, of the mRNA-1083 group compared to the Fluzone HD group for the influenza strains were 1.155 for A/H1N1, 1.063 for A/H3N2 and 1.118 for B/Victoria. The GMR of mRNA-1083 compared to Spikevax for the SARS-CoV-2 variant Omicron XBB.1.5 was 1.641. In the 50 to 64 years of age cohort the GMRs of the mRNA-1083 group compared to the Fluarix group for the influenza virus strains were 1.414 for A/H1N1, 1.380 for A/H3N2, and 1.216 for B/Victoria. The GMR of mRNA-1083 compared to Spikevax for the SARS-CoV-2 variant Omicron XBB.1.5 was 1.308. Immunogenicity was also tested against the B/Yamagata strain of influenza and mRNA-1083 met non-inferiority criteria in both age cohorts. Due to the disappearance of the B/Yamagata lineage from circulation, WHO has recommended a trivalent influenza vaccine composition without B/Yamagata for 2024/2025 vaccines. mRNA-1083 showed an acceptable tolerability and safety profile. The majority of solicited adverse reactions were grade 1 or 2 in severity and consistent with the licensed vaccines used in the trial. The most commonly solicited adverse reactions were injection site pain, fatigue, myalgia and headache. Moderna plans to present the Phase 3 clinical data for mRNA-1083 at an upcoming medical conference as well as submit it for publication. The company will engage with regulators on next steps.

06:51 EDT Enservco says NYSE American begins procedures to delist common stock - Enservco announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Enservco from the Exchange. NYSE Regulation has determined that the company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide as the company was unable to attain a minimum of $6.0 million of stockholders' equity by June 9, 2024; the end of the maximum 18-month compliance plan period. The company has a right to a review of staff's determination to delist the common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange.

06:46 EDT Teladoc names Chuck Divita as CEO - Teladoc Health announced that its Board of Directors has appointed Charles "Chuck" Divita, III, as CEO, effective immediately. Concurrent with his role as CEO, Divita has also joined Teladoc Health's Board of Directors as of June 10. Divita joins Teladoc Health from GuideWell, a health solutions organization which includes Florida Blue, the market leading health plan in Florida, where he served as Executive Vice President, Commercial Markets.

06:34 EDT AIG completes deconsolidation of Corebridge Financial - American International Group (AIG) announced it has met the requirements for the deconsolidation of Corebridge Financial (CRBG) for accounting purposes. The deconsolidation is a result of AIG's decision to waive its right to majority representation on the Corebridge Financial Board of Directors and the resignation of Chris Schaper, Executive Vice President, Global Chief Underwriting Officer, AIG, from Corebridge Financial's Board of Directors. Zaffino will continue as Chairman of the Corebridge Financial Board of Directors which has been reduced to 12 members. AIG owns approximately 48.35% of Corebridge Financial's common stock.

06:26 EDT AstraZeneca's sNDA for Tagrisso granted Priority Review in U.S. - AstraZeneca's supplemental New Drug Application, sNDA, for has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer, NSCLC, after chemoradiotherapy, CRT. If approved, Tagrisso will be indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 mutations. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the fourth quarter of 2024. The sNDA is based on data from the LAURA Phase III trial recently presented during the Plenary Session at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in The New England Journal of Medicine. In the trial, Tagrisso reduced the risk of disease progression or death by 84% compared to placebo as assessed by blinded independent central review. Median progression-free survival was 39.1 months in patients treated with Tagrisso versus 5.6 months for placebo.

06:06 EDT Bitfarms adopts shareholder rights plan - Bitfarms announced that its board has unanimously approved the adoption of a shareholder rights plan pursuant to a shareholder rights plan agreement entered into with TSX Trust Company, as rights agent, dated June 10. The company said the Rights Plan is being adopted to preserve the integrity of our previously announced strategic alternatives review process and is in the best interests of all Bitfarms' shareholders.

06:04 EDT Zymeworks: China NMPA accepts BLA for zanidatamab - Zymeworks (ZYME) announced that the Center for Drug Evaluation of the National Medical Products Administration in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene (BGNE) for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8M milestone payment. Zymeworks also remains eligible to receive up to $164M based on additional milestones plus royalties on product sales in the Asia Pacific region. Under the terms of its collaboration with BeiGene regarding zanidatamab, Zymeworks has received $53M in upfront and milestone payments as well as certain co-development funding for zanidatamab clinical studies, not including the $8M milestone payment Zymeworks is eligible to receive in connection with the NMPA's acceptance of the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Through our collaboration with BeiGene on zanidatamab, we remain eligible to receive up to $164M in additional development and commercial milestones together with tiered royalties of up to 19.5% of net sales in BeiGene territories.

06:01 EDT Comstock Mining expands partnership with RenFuel - Comstock announced advances on amended agreements with RenFuel K2B AB involving the development of RenFuel's pre-existing, planned biorefinery project at a pulp and paper mill in Sweden. The amendments also anticipate expanding the scope of the Comstock partnership with RenFuel in the European markets. These amendments support the liquidation of RenFuel K2B Lignolproduktion AB, a majority owned RenFuel subsidiary originally formed to administer RenFuel's previously planned Swedish biorefinery as part of a joint venture with Preem, thereby better positioning both parties for construction and operation of a larger scale commercial facility based on the joint Comstock-RenFuel technologies throughout Europe, following construction of Comstock's first planned facilities in the Americas. The liquidation of the RenFuel-Preem JV does not alter any of the agreements or terms between Comstock and RenFuel, other than Comstock declining its option to step into the JV. Neither Comstock nor RenFuel have any funding obligations into the JV and are not, in any way, subject to any of the liquidation proceedings.

05:11 EDT Noble Corp. increases quarterly dividend 25% to 50c per share - Additionally, Noble announced that its board of directors has approved a 25% increase in its quarterly dividend to 50c per share, starting with the dividend which is to be paid in the third quarter of 2024. Noble's board of directors approved an interim dividend of 50c per share for the third quarter of 2024. This dividend is in addition to the 40c dividend previously announced which is expected to be paid on June 27 to shareholders of record at close of business on June 6. The 50c dividend is expected to be paid on September 26 to shareholders of record at close of business on September 12. The company intends to continue to pay dividends on a quarterly basis, and the third quarter dividend represents $2.00 on an annualized basis.